Raras
Buscar doenças, sintomas, genes...
Síndrome Stevens-Johnson
ORPHA:36426CID-10 · L51.1CID-11 · EB13.0OMIM 608579DOENÇA RARA

A síndrome de Stevens-Johnson é uma forma limitada de necrólise epidérmica tóxica caracterizada pela destruição e descolamento do epitélio da pele e das membranas mucosas, envolvendo menos de 10% da área de superfície corporal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A síndrome de Stevens-Johnson é uma forma limitada de necrólise epidérmica tóxica caracterizada pela destruição e descolamento do epitélio da pele e das membranas mucosas, envolvendo menos de 10% da área de superfície corporal.

Pesquisas ativas
3 ensaios
41 total registrados no ClinicalTrials.gov
Publicações científicas
5.237 artigos
Último publicado: 2026 Mar

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: L51.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
9 sintomas
👁️
Olhos
4 sintomas
🫁
Pulmão
3 sintomas
🩸
Sangue
3 sintomas
❤️
Coração
3 sintomas
🧬
Pele e cabelo
1 sintomas

+ 14 sintomas em outras categorias

Características mais comuns

90%prev.
Bolhas anormais na pele
Muito frequente (99-80%)
90%prev.
Perda de peso
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Eritema
Muito frequente (99-80%)
90%prev.
Mácula
Muito frequente (99-80%)
90%prev.
Acantólise
Muito frequente (99-80%)
39sintomas
Muito frequente (9)
Frequente (3)
Ocasional (27)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 39 características clínicas mais associadas, ordenadas por frequência.

Bolhas anormais na peleAbnormal blistering of the skin
Muito frequente (99-80%)90%
Perda de pesoWeight loss
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%
EritemaErythema
Muito frequente (99-80%)90%
MáculaMacule
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico5.237PubMed
Últimos 10 anos200publicações
Pico2025104 papers
Linha do tempo
2026Hoje · 2026🧪 2001Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

HLA-BHLA class I histocompatibility antigen, B alpha chainMajor susceptibility factor inTolerante
FUNÇÃO

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:23209413, PubMed:25808313, PubMed:29531227, PubMed:9620674). May also present self-peptides derived from the

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
E3 ubiquitin ligases ubiquitinate target proteins
MECANISMO DE DOENÇA

Stevens-Johnson syndrome

A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
8283.6 TPM
Baço
6025.1 TPM
Linfócitos
5071.2 TPM
Pulmão
4631.0 TPM
Intestino delgado
2873.0 TPM
OUTRAS DOENÇAS (7)
obsolete pulmonary arterial hypertension associated with connective tissue diseaseTakayasu arteritistemporal arteritisStevens-Johnson syndrome
HGNC:4932UniProt:P01889
IKZF1DNA-binding protein IkarosMajor susceptibility factor inAltamente restrito
FUNÇÃO

Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
NOTCH3 Intracellular Domain Regulates Transcription
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
34.6 TPM
Sangue
30.1 TPM
Linfócitos
21.4 TPM
Intestino delgado
11.1 TPM
Pulmão
10.5 TPM
OUTRAS DOENÇAS (3)
pancytopenia due to IKZF1 mutationsStevens-Johnson syndromeB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
HGNC:13176UniProt:Q13422
HLA-AHLA class I histocompatibility antigen, A alpha chainCandidate gene tested inTolerante
FUNÇÃO

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:10449296, PubMed:12138174, PubMed:12393434, PubMed:1402688, PubMed:15893615, PubMed:17189421, PubMed:19543285

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
E3 ubiquitin ligases ubiquitinate target proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
3020.0 TPM
Linfócitos
2770.5 TPM
Baço
2431.7 TPM
Pulmão
1955.9 TPM
Intestino delgado
1462.0 TPM
OUTRAS DOENÇAS (2)
birdshot chorioretinopathyStevens-Johnson syndrome
HGNC:4931UniProt:P04439

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 PredniSONE (PREDNISONE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

108 variantes patogênicas registradas no ClinVar.

🧬 HLA-A: NM_002116.8(HLA-A):c.*263G>A ()
🧬 HLA-A: NM_002116.8(HLA-A):c.*202A>G ()
🧬 HLA-A: NM_002116.8(HLA-A):c.1094-37T>G ()
🧬 HLA-A: NM_002116.8(HLA-A):c.1045+32C>A ()
🧬 HLA-A: NM_002116.8(HLA-A):c.1013A>T (p.Asp338Val) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 31
2Fase 24
1Fase 11
·Pré-clínico13
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Stevens-Johnson

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

41 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
NCT06926478 · Subconjunctival Humira for Boston KeratoprosthesisEm breve
PHASE1
NCT07014059 · Autologous Serum Obtained by a Closed-Circuit Collection Dev…Em breve
PHASE2
NCT03585946 · Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Ne…Cancelado
NCT02739295 · G-CSF in the Treatment of Toxic Epidermal NecrolysisConcluído
PHASE4
NCT02987257 · NATIENS: Optimal Management and Mechanisms of SJS/TENConcluído
PHASE3
NCT04313725 · Evaluation of Tangible Boost for Patients With Stevens Johns…Encerrado
NA
NCT06474078 · Study To Evaluate The Efficacy Of Tofacitinib In Patients Wi…Concluído
NA
NCT02945176 · Safety and Performance Study of the ARGOS-IO System in Patie…Concluído
NA
NCT06522048 · SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune…Concluído
NCT05520086 · Clinical Trial to Evaluate Safety and Efficacy of Cell Thera…UNKNOWN
PHASE1, PHASE2
NCT06263140 · Vitamin D Levels in Non-immediate Drug Hypersensitivity Case…Concluído
NCT05320653 · Nutritional and Metabolic Management of Toxidermia Patients …Concluído
NCT05284929 · Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and…UNKNOWN
NCT05145959 · Meibomian Gland Probing in the Sub-Acute Phase of Patients W…UNKNOWN
NA
NCT01582880 · Use of Cross-linked Donor Corneas as Carriers for the Boston…Concluído
PHASE1, PHASE2
NCT02574988 · Severe Cutaneous Adverse Reactions in ThailandUNKNOWN
NCT03839069 · Minor Salivary Gland Transplantation for Cicatrizing Conjunc…UNKNOWN
NA
NCT02126020 · Topical Infliximab in Autoimmune Eyes With KeratoprosthesisCancelado
PHASE1, PHASE2
NCT03046914 · HLA-B*5801 Screening to Prevent Allopurinol-induced Severe C…UNKNOWN
NA
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.708 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.708

#1

Mechanisms and Targeted Therapeutic Strategies for Inflammation and Renal Fibrosis in Hyperuricemic Nephropathy.

Cell biochemistry and function2026 Feb

Hyperuricemia (HUA) is a growing global health issue driven by economic development and lifestyle changes. Approximately 75% of uric acid in humans is excreted renally. Excess uric acid deposits in renal tissues, promoting tubulointerstitial fibrosis and leading to hyperuricemic nephropathy (HN), which is characterized by urate crystal deposition, chronic interstitial nephritis, and renal fibrosis. The pathogenesis and progression of HN involves dysregulated activation of multiple signaling pathways, including MAPK, Nrf2/HO-1/NQO1, PI3K/AKT, and ASK1/JNK/c-Jun pathways, which facilitate disease progression through the production of pro-inflammatory cytokines and other mediators. Current treatments primarily consist of urate-lowering drugs such as allopurinol, febuxostat, benzbromarone, and probenecid, but their use is constrained by adverse effects including hepatotoxicity, nephrotoxicity, and Stevens-Johnson syndrome. Therefore, targeting inflammatory and fibrotic mechanisms presents a promising therapeutic approach. This review outlines key molecular pathways in HN, discusses contemporary research challenges, and suggests future directions for improved therapeutic strategies.

#2

Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy.

Indian journal of pediatrics2026 Jan 23

To compare the efficacy of sodium valproate (VPA) and levetiracetam (LEV) as initial maintenance monotherapy in children with new-onset epilepsy. This randomised controlled trial was conducted in tertiary pediatric epilepsy and neurology clinics. Children 2-18 y with new-onset epilepsy were enrolled as participants. Patients were prescribed VPA (n = 58) or LEV (n = 58) at 20 mg/kg/d in two doses with increments of 20 mg/kg/d to a maximum of 60 mg/kg/d (Maximum daily dose: VPA 2 g/d and LEV 3 g/d). Primary outcome was the proportion of patients who achieved seizure control for three consecutive months. Secondary outcomes included the proportion of patients who achieved a 50% reduction in seizures from baseline and those who developed side-effects. A total of 116 patients were analysed using intention-to-treat analysis. There was no difference in the primary outcome between LEV vs. VPA groups [58.6% vs. 65.5%; relative risk (RR) 0.89 (95% CI, 0.67-1.19), p = 0.444]. There was no difference in patients who achieved a 50% seizure reduction from baseline between the two groups (70.7% vs. 70.7%) and side-effect profile (32.8% vs. 46.6%, p = 0.128) other than median (IQR) weight gain (kg), which was significantly lower in the LEV group (1.35, 0.70-1.60) as compared to the VPA group (2.15, 1.40-2.60) (p < 0.001). One patient in the VPA group had Stevens-Johnson syndrome. No mortality occurred. No difference was noted between sodium valproate and levetiracetam in seizure control. With a favorable side-effect profile, levetiracetam can be safely considered as initial maintenance monotherapy in children with new-onset epilepsy.

#3

A case of Stevens-Johnson syndrome triggered by Mycoplasma infection.

Journal of oral science2026

Stevens-Johnson syndrome (SJS) is a rare, potentially life-threatening mucocutaneous disorder, which is often triggered by infections such as Mycoplasma pneumoniae. This report describes a 19-year-old woman who initially presented with oral erosions and painful blisters, along with fever and cough. Oral lesions preceded skin and ocular involvement, and tests confirmed Mycoplasma-associated SJS. She responded to steroid pulse therapy but relapsed at 3 months and was then successfully treated. Oral manifestations may be early SJS indicators; thus, prompt recognition and interdisciplinary care by oral health professionals are vital for improving clinical outcomes.

#4

Validation of International Classification of Diseases Codes for Dermatologic Conditions: A Systematic Review.

JAMA dermatology2026 Feb 01

Accurate classification of dermatologic conditions using International Classification of Diseases (ICD) codes is essential for research that uses large administrative datasets. Misclassification can be associated with biased epidemiologic estimates and misleading conclusions in population-based studies. To systematically identify and evaluate validated classification approaches for dermatologic conditions using ICD codes in US-based administrative, claims, or electronic health record data. A systematic review was conducted that was registered with PROSPERO (CRD420250654233) and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search of Ovid MEDLINE, Embase, Web of Science, and CINAHL was conducted for studies published from January 1, 2000, to October 21, 2025. The data were analyzed in October 2025. Eligible studies evaluated International Classification of Diseases, Ninth Revision (ICD-9) or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes used to identify dermatologic conditions in US-based datasets and reported at least 1 classification metric (eg, positive predictive value). To minimize selection and extraction bias, all screening and data extraction were performed independently by 2 reviewers, with discrepancies resolved by consensus. A total of 59 studies met inclusion criteria. Most reported positive predictive value, with few reporting sensitivity or specificity. Classification accuracy varied widely by condition and coding strategy. Studies included inflammatory and autoimmune conditions (eg, acne vulgaris, perioral dermatitis, psoriasis, palmoplantar pustulosis, hidradenitis suppurativa, atopic dermatitis, prurigo nodularis, dermatomyositis, cutaneous lupus erythematosus, pyoderma gangrenosum, cutaneous sarcoidosis, pemphigus, pemphigoid, granuloma annulare, alopecia areata, and vitiligo), actinic keratosis and skin cancer, pigmentary and hair disorders (eg, androgenic alopecia, cicatricial alopecia, lichen planopilaris, and melasma), drug reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), and infections (eg, herpes zoster, herpes simplex virus, and cellulitis or abscess). Classification algorithms that incorporated 2 or more codes, dermatologist attribution, or treatment/procedural data often achieved the highest accuracy. Conditions lacking validated algorithms included seborrheic dermatitis, rosacea, fungal infections, and specific alopecia subtypes. This systematic review provides a summary of the most accurate classification approaches to identify various dermatologic conditions in large administrative datasets. These results may inform study designs when using these datasets. In addition, some common conditions lack validated classification approaches, highlighting important areas for future research. As administrative and electronic health record data increasingly support dermatology research, use of rigorously validated algorithms will be essential for generating trustworthy findings.

#5

Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.

Japanese journal of clinical oncology2026 Feb 13

Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP, with a focus on cutaneous adverse events (AEs). We retrospectively analyzed 48 Japanese patients with la/mUC treated with first-line EVP at 12 centers between November 2024 and March 2025. Clinical data, AEs, and tumor responses were collected. Cutaneous AEs were evaluated for onset, severity, and management. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The patients' median age was 76 years, and 89.6% were cisplatin-ineligible. All patients experienced treatment-related AEs, with 39.6% having grade ≥3 events. Cutaneous AEs occurred in 60.4%, including 18.8% with grade ≥3 rash and two cases of Stevens-Johnson syndrome. The median time to discontinuation due to AEs was 14 days. The overall response rate was 39.6%, and the disease control rate was 69%, rising to 87% among 38 evaluable patients. EVP demonstrated favorable early efficacy in Japanese patients but was associated with frequent early discontinuation due to AEs, particularly cutaneous toxicity. Early skin care and interdisciplinary management are essential. These findings support EVP use while emphasizing AE management and patient-centered care.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.889 artigos no totalmostrando 197

2026

Cutaneous adverse drug reactions in patients with congenital heart disease: a systematic review with focus on perioperative outcomes.

BMC cardiovascular disorders
2026

The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.

Cureus
2026

The effects of anabolic-androgenic steroids administration on oral health in humans: a scoping review.

The Journal of sports medicine and physical fitness
2026

A Rash Decision: Mycoplasma-Induced Mucositis in a Young Adult.

Cureus
2026

Sintilimab-induced toxic epidermal necrolysis complicated in advanced gastric cancer: a case report and literature review.

Frontiers in immunology
2026

Lamotrigine-induced Stevens-Johnson syndrome: a systematic review of case reports and case series.

Clinical toxicology (Philadelphia, Pa.)
2026

Beyond the Target: Re-Emergence of Mycoplasma pneumoniae Supports Reclassification of Adult Mucocutaneous Eruptions.

International journal of dermatology
2026

SEVERE TOXIC EPIDERMAL NECROLYSIS COMPLICATED BY ACUTE KIDNEY INJURY: DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS.

Georgian medical news
2026

Toxic epidermal necrolysis in a preschooler associated with adenovirus respiratory infection: A case report.

JAAD case reports
2026

SCORTEN and Novel Prognostic Markers in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis.

The Australasian journal of dermatology
2026

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Cases Secondary to Topical Medications.

The Australasian journal of dermatology
2026

Cutaneous and non-cutaneous diseases due to Mycoplasma pneumoniae in children.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2026

Predictors of Survival and Length of Stay in Steven Johnson syndrome and toxic epidermal necrolysis: A single centre retrospective study of 111 patients.

Journal of burn care &amp; research : official publication of the American Burn Association
2025

Clinical Profile and Visual Rehabilitation with Mini-Scleral Device in Irregular Corneas at a Tertiary Eye Hospital : An Observational Study.

JNMA; journal of the Nepal Medical Association
2026

Prediction of antibiotic-associated cutaneous adverse drug reactions using electronic health record foundation models.

NPJ digital medicine
2026

A narrative review of drug-induced haemophagocytic lymphohistiocytosis: A rare but relevant differential diagnosis.

International archives of allergy and immunology
2026

Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions.

The Journal of dermatological treatment
2026

Evaluation of drug causality in SJS/TEN: The role of the lymphocyte transformation test and conventional/modified IFN-γ ELISpot assays.

The World Allergy Organization journal
2026

A rare drug reaction: Toxic epidermal necrolysis following polymyxin B administration in a post-Bentall procedure.

Indian journal of pharmacology
2026

From Respiratory Pathogen to Systemic Threat: Rethinking Mycoplasma pneumoniae Infections.

Microorganisms
2026

Reactive Infectious Mucocutaneous Eruption (RIME) Associated with Mycoplasma pneumoniae: Clinical and Immunological Insights from Pediatric Cases.

Microorganisms
2026

Stevens-Johnson Syndrome And Toxic Epidermal Necrolysis Possibly Related to Daptomycin And Ceftaroline in a Patient With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: A Case Report and Brief Review.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
2026

The effect of different therapies and complete blood cell count-derived inflammatory biomarkers on the prognosis of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Clinical and experimental dermatology
2026

Amitriptyline Induced Life-Threatening Steven-Johnson Syndrome: Case Report.

Clinical case reports
2026

A 10-Year Retrospective Cohort Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at the Royal Brisbane and Women's Hospital.

The Australasian journal of dermatology
2026

Nevirapine-induced Stevens-Johnson Syndrome in an HIV-exposed neonate: A case report.

IDCases
2026

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer: A case report.

Medicine
2026

Insights into Severe Cutaneous Adverse Drug Reactions: A 5-Year Retrospective Analysis of Stevens- Johnson Syndrome- Toxic Epidermal Necrolysis and Drug Rash with Eosinophilia and Systemic Symptoms.

Indian dermatology online journal
2025

Stevens-Johnson syndrome as the presenting manifestation of human immunodeficiency virus and syphilis coinfection.

Dermatology online journal
2026

Adverse Drug Reaction to Paracetamol: Case Report of Oral Manifestation of Stevens-Johnson Syndrome in Children.

International medical case reports journal
2026

Molecular Insights Into TNF-α and IFN-γ-Induced Epithelial Cell Death in Toxic Epidermal Necrolysis.

Journal of biochemical and molecular toxicology
2026

Mechanisms and Targeted Therapeutic Strategies for Inflammation and Renal Fibrosis in Hyperuricemic Nephropathy.

Cell biochemistry and function
2026

A case of delayed-onset Stevens-Johnson syndrome following co-amoxiclav administration in a 98-year-old female.

The International journal of risk &amp; safety in medicine
2026

Diagnosis and Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Patients: A Systematic Review of Clinical Guidelines and Consensus Statements.

Pediatric dermatology
2026

[Drug-induced hypersensitivity reactions : Pulmonary manifestations and radiological characteristics].

Radiologie (Heidelberg, Germany)
2026

Toxic Epidermal Necrolysis in Pregnancy: A Case Report.

Cureus
2026

A case of toxic epidermal necrolysis associated with vonoprazan, a potassium-competitive acid blocker.

JAAD case reports
2026

Nimesulide-Associated Generalized Bullous Fixed Drug Eruption: A Rare Pharmacovigilance Case Report.

Cureus
2026

Factors associated with penicillin and sulfonamide allergy and Stevens-Johnson syndrome/toxic epidermal necrolysis.

AIDS (London, England)
2026

Racial Disparities in Severe Cutaneous Adverse Reactions: A Report of Two Cases on Preventable Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Prescription Errors Through Medication Stewardship.

Cureus
2026

Treatment of toxic epidermal necrosis lesions with ovine forestomach matrix.

Journal of surgical case reports
2025

Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2026

Efficacy of Cultivated Oral Mucosal Epithelial Transplantation for Limbal Stem Cell Deficiency in Stevens-Johnson Syndrome Versus Other Etiologies.

Cornea
2026

Cyclosporine use in paediatric dermatologic conditions: A comprehensive review of therapeutic applications.

British journal of clinical pharmacology
2026

Development of a health-related quality of life outcome measure for adults with Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) - QoLTEN: An international multidisciplinary DELPHI consensus survey.

The British journal of dermatology
2026

Effective management of pembrolizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with upadacitinib.

JAAD case reports
2026

Cutaneous Toxicities of Small Molecules in Targeted Cancer Therapy Part I - Mechanisms of Toxicity.

Journal of the American Academy of Dermatology
2026

Cutaneous Toxicities of Small Molecules in Targeted Cancer Therapy Part II - Approach to Management and Treatment.

Journal of the American Academy of Dermatology
2026

The Outcomes of SJS/TEN: A Nationwide Analysis.

Journal of burn care &amp; research : official publication of the American Burn Association
2026

Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology.

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2025

Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Frontiers in medicine
2025

Immune checkpoint inhibitor-related Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective analysis of 21 cases.

Frontiers in immunology
2025

Real-World Data on Severe Cutaneous Adverse Reactions to Drugs.

Pharmaceuticals (Basel, Switzerland)
2026

Epidemiological characteristics of severe skin adverse reactions caused by immune checkpoint inhibitors based on case reports.

International journal of clinical pharmacology and therapeutics
2026

Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy.

Indian journal of pediatrics
2025

Severe cutaneous adverse drug reactions due to antituberculosis drugs and their management.

Northern clinics of Istanbul
2025

Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study.

Frontiers in immunology
2026

Evidence of a Therapeutic Window for TNF-α Inhibitor and Intravenous Immunoglobulin Benefits in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Treatment: A Multicenter 6-Year Retrospective Study.

The journal of allergy and clinical immunology. In practice
2026

The Role of the Boston Keratoprosthesis in Severe Ocular Surface Disease and Autoimmune Diseases.

Seminars in ophthalmology
2025

Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.

Frontiers in pharmacology
2026

Stevens-Johnson syndrome/toxic epidermal necrolysis as the initial presentation of paraneoplastic anti-TIF1-γ dermatomyositis.

SAGE open medical case reports
2026

Drug-Induced Fuchs Syndrome With Isolated Oral Involvement: A Rare Case Report.

Case reports in dermatological medicine
2026

A case of Stevens-Johnson syndrome triggered by Mycoplasma infection.

Journal of oral science
2025

[A Case of Toxic Epidermal Necrolysis during Chemotherapy for Advanced Gastric Cancer].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2026

Clinicopathologic and Immunohistochemical Features of Enfortumab Vedotin-Induced Cutaneous Toxicity.

International journal of dermatology
2026

Generalized Bullous Fixed Drug Eruption: A Systematic Review.

The journal of allergy and clinical immunology. In practice
2025

Microbiological findings and antimicrobial resistance dynamics in pathogens isolated from patients with toxic epidermal necrolysis: a single center experience.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne
2026

Comparative analysis of cytotoxic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis using ex vivo human epidermis.

Journal of dermatological science
2025

Restoring the mucin barrier: Advances in secretagogue therapies for ocular surface disorders.

Taiwan journal of ophthalmology
2026

Outcome of sutureless amniotic membrane dressing ring for acute Stevens-Johnson syndrome with severe ocular involvement: A case report of 5 patients.

Medicine
2026

Guidelines for the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 2025 Supplement.

The Journal of dermatology
2026

Osteo-odonto-keratoprosthesis: a surgical procedure for treating advanced corneal diseases.

The Saudi dental journal
2026

Validation of International Classification of Diseases Codes for Dermatologic Conditions: A Systematic Review.

JAMA dermatology
2026

Just the facts: diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.

CJEM
2026

IL-6 as a Potential Sensitive Serum Biomarker in Stevens-johnson Syndrome/Toxic Epidermal Necrolysis: Two Case Reports.

Recent advances in inflammation &amp; allergy drug discovery
2026

Blistering Drug Eruptions: Diagnostic Challenges and Management in Clinical Practice: Unmasking the Cause: A Grand Rounds Review of Blistering Drug Eruption.

The journal of allergy and clinical immunology. In practice
2026

Longitudinal Immune Profiling of T Cell Exhaustion During IL-17A Blockade in a Patient With HLA-B27-negative Spondyloarthritis and Sjögren's Syndrome: A Case Report.

In vivo (Athens, Greece)
2025

The Gut Microbiome in Stevens-Johnson Syndrome and Sjögren's Disease: Correlations with Dry Eye.

Microorganisms
2025

Risk factors and predictive score for phenytoin-induced cutaneous reactions.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Case Report: Successful weaning after 113 days of VV-ECMO in a pediatric patient with severe ARDS following Stevens-Johnson syndrome.

Frontiers in pediatrics
2025

A scoping review of case reports and small case series in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Journal of the European Academy of Dermatology and Venereology : JEADV
2026

Severe Cutaneous Signs of Hipersensitivity to Drugs in a Pediatric Hospital.

Actas dermo-sifiliograficas
2025

Reactive Infectious Mucocutaneous Eruption Following Isolated Rhinovirus Infection: Clinical Presentation and Treatment Response.

Cureus
2026

The Predictive Value of Inflammatory Markers in the Severity and Mortality Risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

The Journal of dermatology
2026

Increased TNF-α in SJS/TEN induced by PD-1 inhibitors supports the combination therapy of etanercept and systemic corticosteroids.

Molecular immunology
2025

Delayed presentation of pembrolizumab-induced SJS-TEN overlap syndrome.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2025

Mycoplasma pneumoniae-induced rash and mucositis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
2026

Cheilitis: a comprehensive review and a new clinical classification proposal. Part 1: Isolated cheilitis.

Italian journal of dermatology and venereology
2025

[Clinical Approach to the Patient With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Part II].

Revista medica de Chile
2026

Evidence for the Use of Janus Kinase (JAK) Inhibitors in the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Scoping Review.

The Australasian journal of dermatology
2025

Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases.

Frontiers in pharmacology
2025

Toxic Epidermal Necrolysis Induced by First-Line Helicobacter pylori Eradication Therapy: A Case Report.

The Korean journal of helicobacter and upper gastrointestinal research
2025

Paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: patterns and outcomes in a retrospective Pakistani cohort.

BMJ paediatrics open
2025

Chronic Ocular Complications in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical Features and Surgical Management in a Brazilian Tertiary Center.

Cornea
2025

Long-Term Outcomes of Boston Type I Keratoprosthesis After Minor Salivary Gland Transplantation and Labial Mucous Membrane Grafting as an Alternative Treatment for Stevens-Johnson Syndrome.

Cornea
2025

An Atypical Trigger of Stevens-Johnson Syndrome with Severe Ocular Complications.

Irish medical journal
2025

Ocular administration of brinzolamide leading to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap: A case report and review.

Medicine
2026

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Topical Carbonic Anhydrase Inhibitors: A Literature Review.

Actas dermo-sifiliograficas
2026

Diagnostic sensitivity and specificity of mucosal involvement versus skin biopsy for Stevens-Johnson syndrome/toxic epidermal necrolysis.

Journal of the American Academy of Dermatology
2025

Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment.

Clinical and translational science
2026

A Case of Generalized Fixed Drug Eruption Showing the Conjunctival Involvement With CD4+ Tissue-Resident Memory T Cell Accumulation.

The Journal of dermatology
2025

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by tislelizumab: a case report and literature review.

Frontiers in immunology
2025

Evaluation of umbilical cord blood serum eye drops for severe dry eye in two distinct populations-Sjögren's syndrome and mustard gas-induced ocular injury: Protocol for a pilot randomized clinical trial.

PloS one
2026

Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.

International journal of clinical pharmacy
2025

Severe cutaneous adverse reaction to amoxicillin-clavulanate: Pediatric toxic epidermal necrolysis in the Gulf: A case report and literature review.

International journal of surgery case reports
2025

Incidence and clinical patterns, severity and preventability of cutaneous adverse drug reactions among hospitalized patients in a tertiary centre.

The Medical journal of Malaysia
2025

Cheilitis: a comprehensive review and a new clinical classification proposal. Part 2: Cheilitis associated with dermatological diseases, systemic diseases, or drug reactions.

Italian journal of dermatology and venereology
2025

Reactive Infectious Mucocutaneous Eruption (RIME) Associated With Rhinovirus and HHV-7 in a 14-Year-Old Boy.

Case reports in pediatrics
2025

Levofloxacin-Induced Fuchs Syndrome: A Rare Atypical Stevens-Johnson Syndrome Variant With a Comprehensive Literature Review.

Case reports in medicine
2025

Bioinformatics analysis of Rickettsia typhi autoimmune associations and screening of Streptomyces-derived inhibitors.

BioData mining
2025

Case Report: Zonisamide-induced DRESS syndrome with progression toward SJS: the first Chinese case and review of the literature on ZNS-associated SCARs.

Frontiers in medicine
2025

Examination of histopathological findings in Mycoplasma pneumoniae-induced rash and mucositis case.

Pediatrics international : official journal of the Japan Pediatric Society
2026

Comparative Impact of NSAIDs Versus Acetaminophen on Mortality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Cohort Study of 2484 Patients From a Nationwide Inpatient Database.

The Journal of dermatology
2025

Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety.

Journal of clinical medicine
2026

Mycoplasma pneumoniae-Induced Rash and Mucositis: Clinicopathologic Characterization of 11 Cases.

Journal of cutaneous pathology
2026

Umbilical cord-derived mesenchymal stem cell therapy for acute Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with severe ocular involvement.

The ocular surface
2025

Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of current management and changing trends.

Indian journal of ophthalmology
2025

Update on dermatological toxicities of immune checkpoint inhibitors.

Presse medicale (Paris, France : 1983)
2025

Immune Checkpoint Inhibitor-Related Epidermal Necrosis: Terminology, Pathology, and Clinical Implications.

Archives of pathology &amp; laboratory medicine
2025

Cost-effectiveness analysis of pharmacogenetic-guided antiseizure medication therapy based on the risk of HLA-A*31:01 allele variants in Japan.

PCN reports : psychiatry and clinical neurosciences
2025

Surgical management of chronic Stevens-Johnson syndrome.

Frontiers in medicine
2026

Characterization of the spectrum of cutaneous adverse reactions to enfortumab vedotin: A retrospective cohort study.

Journal of the American Academy of Dermatology
2026

Prevalence of dermatologic side effects of mood stabilizers in bipolar disorder: A systematic review and meta-analysis.

Journal of psychiatric research
2026

Analysis of clinical characteristics of tislelizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Chinese population: a systematic review.

Cutaneous and ocular toxicology
2025

Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated With Mebendazole Use.

Basic &amp; clinical pharmacology &amp; toxicology
2025

Tislelizumab-associated toxic epidermal necrolysis in an esophageal cancer patient: a case report.

Frontiers in immunology
2026

Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.

Japanese journal of clinical oncology
2025

Titel: Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study.

Pharmacoepidemiology and drug safety
2025

[Severe lichenoid drug eruption with oral involvement resembling Stevens-Johnson syndrome induced by carbamazepine: A case report].

Semergen
2025

Apalutamide-induced life-threatening dermatologic toxicity: Clinical histopathological correlations and salvage therapies in four cases: Case report series.

Medicine
2025

Allogeneic Umbilical Cord Blood Serum Eyedrops for the Treatment of Severe Dry Eye Disease Patients.

International journal of molecular sciences
2026

Recovering From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

JAMA dermatology
2025

Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications.

EXCLI journal
2025

Cytokine profile-guided management of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): A management algorithm useful for guiding the selection of treatment options.

Allergology international : official journal of the Japanese Society of Allergology
2025

A Case of Immunotherapy-Induced Balanitis.

Cureus
2025

Hypoalbuminemia and Nutritional Status in Docetaxel-Induced Erythema Multiforme: A Case Report.

Cureus
2025

Skin-adverse drug reactions in the elderly: An underestimated and avoidable issue.

Annales de dermatologie et de venereologie
2026

Stevens-Johnson Syndrome Induced by Radiotherapy Alone: A Rare and Well-Documented Case Without Concomitant Drug Exposure.

International journal of dermatology
2025

Severe pneumonia with Mycoplasma pneumoniae-induced raѕh and mucositis in an 8-year-old boy.

Paediatrics and international child health
2025

Surgery for Symblepharon Developed Due to Stevens-Johnson Syndrome: Modified Ring Procedure Performed Through Amniotic Membrane Transplantation and a 6 French Aspiration Catheter.

Romanian journal of ophthalmology
2025

Stevens-Johnson syndrome or toxic epidermal necrolysis from antihypertensive medications: A systematic review of cases.

Medicine
2026

Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids.

Journal of the American Academy of Dermatology
2025

Recurrent Reactive Infectious Mucocutaneous Eruption (RIME) in a Pediatric Patient Triggered by Mycoplasma pneumoniae and Enterovirus Coinfection.

Cureus
2025

An Atypical Case of Toxic Epidermal Necrolysis Associated With Ceftriaxone.

Cureus
2025

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report.

Annals of medicine and surgery (2012)
2025

Pediatric vs adult Stevens Johnson syndrome/toxic epidermal necrolysis: Ocular outcomes and the role of amniotic membrane.

The ocular surface
2025

Psychological Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis.

The Australasian journal of dermatology
2025

Ofloxacin, paracetamol and cefixime induced Stevens-Johnson syndrome - toxic epidermal necrolysis in an adult female patient: a case report.

Journal of pharmaceutical health care and sciences
2026

JAAD Game Changer: Retrospective cohort study characterizing PD-1/PD-L1 checkpoint inhibition associated Stevens-Johnson syndrome and toxic epidermal necrolysis.

Journal of the American Academy of Dermatology
2025

Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN.

JAMA oncology
2025

Ocular manifestations in Stevens‒Johnson syndrome/toxic epidermal necrolysis in cancer patients.

The ocular surface
2025

HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US.

JAMA dermatology
2025

Summary of the Best Evidence on Skin-Mucosal Care in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Advances in skin &amp; wound care
2025

More than Mucositis: Pediatric RIME Following Co-Infection with SARS-CoV-2 and Mycoplasma pneumoniae-A Case Report and Mini-Review.

Infectious disease reports
2026

Toxic Epidermal Necrolysis and Mortality: A Danish Cohort Study With 30 Years of Follow-Up.

The Journal of dermatology
2025

Mycoplasma pneumoniae-Associated Mucositis: A Diagnostic Dilemma.

Clinical case reports
2025

Postoperative Staphylococcal Toxic Shock Syndrome in a Patient Following Right Knee Fracture Repair: A Case Report.

Cureus
2026

Fatal Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Advanced Lung Adenocarcinoma.

The Kaohsiung journal of medical sciences
2026

[Current dermatology guidelines in Germany: a selection of clinically relevant recommendations].

Dermatologie (Heidelberg, Germany)
2026

Biologic therapies for dermatologic emergencies: A comprehensive review.

Journal of the American Academy of Dermatology
2026

Long-term cardiovascular morbidity in Stevens-Johnson syndrome: A retrospective TriNetX matched-cohort analysis.

Journal of the American Academy of Dermatology
2025

Pediatric Mycoplasma pneumoniae-induced rash and mucositis in China: clinical spectrum, co-infections and risk factors for recurrence-a retrospective cohort study.

Frontiers in allergy
2025

Unravelling Stevens-Johnson Syndrome: Clinicopathological Insights and Therapeutic Advances.

Seminars in ophthalmology
2025

Amniotic membrane transplantation techniques in acute ocular Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review.

The ocular surface
2025

Relationship Between Chronic Ocular Surface and Meibomian Gland Changes and Clinical Assessment Tool in Cicatricial Conjunctival Diseases.

Ocular immunology and inflammation
2025

Toxic Epidermal Necrolysis and Recurrent Implantation Failure: Unveiling a Rare Phenomenon During Pregnancy.

Clinical case reports
2025

Epidermal necrolysis (Stevens-Johnson syndrome/ toxic epidermal necrolysis) as extensive boundary violation: A qualitative study on the illness experience and care needs of survivors in the context of the first German guideline.

PloS one
2025

[A CASE OF PEDIATRITIC TOXIC EPIDERMAL NECROSIS TRIGGERD BY OVER-THE-COUNTER EYE DROPS].

Arerugi = [Allergy]
2025

Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum reactions to immune checkpoint inhibitor therapy and safety of rechallenge: A retrospective review.

JAAD case reports
2026

Extensive upper aerodigestive tract involvement in metamizole-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.

European annals of otorhinolaryngology, head and neck diseases
2025

Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: age-stratified insights from the FAERS database.

Jornal de pediatria
2025

Clinical course and efficacy of treatment with limbal-rigid contact lens wear for ocular sequelae in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Japanese journal of ophthalmology
2025

Multidisciplinary management of antiepileptic drug-induced toxic epidermal necrolysis in a young woman.

Biomedica : revista del Instituto Nacional de Salud
2025

Myeloperoxidase-positive mononuclear cells predominate over CD3-positive T-lymphocytes in the epidermis of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Virchows Archiv : an international journal of pathology
2025

Clinical Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Based on Hospital Admission Type.

Cutis
2025

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions.

Frontiers in pharmacology
2025

Reactive Infectious Mucocutaneous Eruption: A Rising Enigma.

Acta medica portuguesa
2025

Structured skin care for a patient with toxic epidermal necrolysis caused by anlotinib: Case report.

Medicine
2025

Inhibition of formyl peptide receptor-1-mediated cell death as a therapy for lethal cutaneous drug reactions in preclinical models.

Nature communications
2025

Difficulties in management of ocular surface in the late phase of toxic epidermal necrolysis - a rare case report.

Annals of agricultural and environmental medicine : AAEM
2025

Clinical, pathological and immunological features of toxic-epidermal necrolysis like lupus erythematosus: A systematic review and proposal for diagnostic criteria.

Lupus
2025

Toxic epidermal necrolysis: lessons from three fatal cases.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica
2026

Long-term morbidity and quality of life in survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.

The British journal of dermatology
2025

Stevens-Johnson syndrome/toxic epidermal necrolysis-like acute cutaneous lupus erythematosus.

Medicina clinica
2025

Clinical outcomes of simple limbal epithelial transplantation for limbal stem cell deficiency in a Mexican population.

Indian journal of ophthalmology
2025

Immune checkpoint inhibitor-induced toxic epidermal necrolysis responding to repeated dosing of adjuvant therapy with etanercept.

JAAD case reports
2026

Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions.

European journal of human genetics : EJHG
2025

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Ophthalmic Management and Treatment.

Vision (Basel, Switzerland)
2026

Vulvovaginal involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis: A retrospective review at a tertiary care center (2016-2024).

Journal of the American Academy of Dermatology
2025

Viral Triggers Exposed: A Systematic Review of Virus-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Journal of inflammation research
2025

Photodistributed Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Photodermatology, photoimmunology &amp; photomedicine
2025

Cyclosporine: An Emerging Therapeutic Agent for<br /> Paediatric Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
2025

Oral Manifestations of Pediatric Multisystem Inflammatory Syndrome.

Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
2025

Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.

Frontiers in immunology
2025

A Case of Acetaminophen-induced Toxic Epidermal Necrolysis with Airway Mucosal Lesions.

Internal medicine (Tokyo, Japan)
2025

[Autologous oral mucosal epithelial transplantation in the treatment of bilateral limbal stem cell deficiency].

Vestnik oftalmologii
2025

Azithromycin-Induced Stevens-Johnson Syndrome in a Patient With SARS-CoV-2 and End-Stage Renal Disease.

Cureus
Ver todos os 2.889 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Stevens-Johnson.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Stevens-Johnson

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Mechanisms and Targeted Therapeutic Strategies for Inflammation and Renal Fibrosis in Hyperuricemic Nephropathy.
    Cell biochemistry and function· 2026· PMID 41707030mais citado
  2. Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy.
    Indian journal of pediatrics· 2026· PMID 41575632mais citado
  3. A case of Stevens-Johnson syndrome triggered by Mycoplasma infection.
    Journal of oral science· 2026· PMID 41548906mais citado
  4. Validation of International Classification of Diseases Codes for Dermatologic Conditions: A Systematic Review.
    JAMA dermatology· 2026· PMID 41499108mais citado
  5. Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.
    Japanese journal of clinical oncology· 2026· PMID 41259242mais citado
  6. Suspected Stevens-Johnson Syndrome After Azithromycin and Doxycycline Exposure in an Elderly Woman: A Case Report Showcasing Treatment Based on Clinical Diagnosis.
    Cureus· 2026· PMID 41982575recente
  7. Stevens-Johnson Syndrome following a Single Ampicillin Dose in an Elderly Patient: A Case Report.
    Case Rep Dermatol· 2026· PMID 41969600recente
  8. [DIAGNOSIS AND MANAGEMENT OF SEVERE CUTANEOUS ADVERSE DRUG REACTIONS].
    Arerugi· 2026· PMID 41967940recente
  9. Plasma Cytokine and Chemokine Profile in Hospitalized Toxic Epidermal Necrolysis Patients.
    Clin Exp Dermatol· 2026· PMID 41967128recente
  10. When Infection and Drug Hypersensitivity Converge: An SJS-Like Mucocutaneous Reaction.
    Int J Dermatol· 2026· PMID 41966633recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:36426(Orphanet)
  2. OMIM OMIM:608579(OMIM)
  3. MONDO:0018229(MONDO)
  4. GARD:7700(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q1053948(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Stevens-Johnson
Compêndio · Raras BR

Síndrome Stevens-Johnson

ORPHA:36426 · MONDO:0018229
Prevalência
Unknown
Herança
Not applicable
CID-10
L51.1 · Eritema multiforme bolhoso
CID-11
Ensaios
3 ativos
Início
All ages
Prevalência
0.0 (Europe)
MedGen
UMLS
C0014518
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades